METTL3 drives malignant progression in TP53-mutant prostate cancer.

ABSTRACT:

SUBMITTER: Pu Y 

PROVIDER: S-EPMC12605356 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature